1. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis. Accessed 26 Jan 2022.
2. Food and Drug Agency. Coronavirus (COVID-19) Update: June 25, 2021. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-june-25-2021. Accessed 26 Jan 2022.
3. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html?CDC_AA_refVal=https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html. Accessed 26 Jan 2022.
4. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471–84.
5. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV‑2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e68665.